Wednesday, June 10, 2026

pharma Β· Carcinoma, Non-small-cell Lung Β· Type 2 Diabetes Mellitus Β· LGND

LIGAND PHARMACEUTICALS

LIGAND PHARMACEUTICALS clinical programs β€” 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US HQ
1987 Founded
130 Employees
Public company Type
LGND Β· NYSE Ticker
Company details
Status
Public
HQ
555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US
Founded
1987
Employees
130
Programs
34
Drugs
25
Patents
133
Intelligence Β· Clinical Programs

LIGAND PHARMACEUTICALS projects

3 ClinicalTrials.gov programs sponsored by LIGAND PHARMACEUTICALS.

LIGAND PHARMACEUTICALS has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Intravenous Carbamazepine (IV CBZ)

    LIGAND PHARMACEUTICALS INC

    Epilepsy

    phase 3 small molecule completed

    1 trial
  2. Targretin Gel 1%

    LIGAND PHARMACEUTICALS INC

    Alopecia Areata

    phase 3 small molecule completed

    1 trial
  3. lasofoxifene

    LIGAND PHARMACEUTICALS INC

    Osteoporosis

    phase 3 small molecule completed

    3 trials

Frequently asked questions

How many clinical projects does LIGAND PHARMACEUTICALS have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.